Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 223 for:    test | ( Map: Uganda )

HIV Self Testing of Male Partners of Women in PMTCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03484533
Recruitment Status : Enrolling by invitation
First Posted : April 2, 2018
Last Update Posted : January 17, 2019
Sponsor:
Collaborators:
National Institute of Mental Health (NIMH)
Harvard University
University of North Carolina, Chapel Hill
Information provided by (Responsible Party):
Connie Celum, University of Washington

Brief Summary:
The investigators will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits (HIVST) to HIV-positive pregnant women to provide to their male partner, increases the proportion of male partners who test and link to HIV care or prevention, compared to invitation letters for fast track testing. Pregnant women who are randomized to the arm with secondary distribution of HIVST to their male partners will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. The investigators will offer men confirmatory testing regardless of their HIVST result, counseling, and if negative, pre-exposure prophylaxis (PrEP) and if positive, antiretroviral therapy (ART). The investigators will provide counseling to minimize social harms of HIV self-testing, and additional counseling and referral to social support services when social harms occur. This project will address key challenges in PMTCT B+ programs, by evaluating innovative strategies to increase male partner's knowledge of their HIV status, disclosure, and involvement coupled with offering PrEP to HIV-negative men, ART to HIV-positive men, and encouraging post-partum ART continuation and adherence among HIV-positive women.

Condition or disease Intervention/treatment Phase
ART Adherence PMTCT Linkage to Care HIV PrEP Behavioral: HIV self-test kit Behavioral: Standard of Care Not Applicable

Detailed Description:

Uganda has the fifth highest HIV burden globally and one of the highest fertility rates in Africa. Prevention of mother-to-child HIV transmission Option B+ (PMTCT B+) is national policy in Uganda. To maximize the prevention and clinical benefits of PMTCT B+, the challenges of low HIV testing by male partners and high rates of post-partum discontinuation of ART, insufficient adherence, and incomplete viral suppression need to be addressed. Women may be more likely to continue ART long-term and have higher adherence post-partum if their partner is tested, there is mutual disclosure of HIV status, and their partner takes ART or PrEP, depending on his status. Innovative approaches are needed to allow men to test in settings other than busy antenatal clinics, preferably where they have privacy, are comfortable and do not miss work. Innovative HIV testing technology -HIVST- could increase male partner's uptake of HIV testing, and prevention (PrEP) or ART (for all HIV-positive men). This study has been designed to address this gap through an enhanced PMTCT B+ program with HIV self-testing, and linkage to PrEP or ART, for male partners.

In a demonstration project the investigators recently completed among mutually disclosed East African HIV serodiscordant couples (the Partners Demonstration Project), integrated ART and PrEP delivery with time-limited PrEP for the HIV-negative partner as a 'bridge' until the HIV-positive partner was on ART for six months, and achieved viral suppression, was very acceptable, achieved very high uptake and adherence to ART and PrEP, and nearly eliminated HIV transmission. This protocol builds on that demonstration project by evaluating whether PMTCT outcomes are improved by increasing uptake of HIV testing and PrEP among HIV-negative men whose pregnant partner is HIV-positive. PrEP for HIV-negative male partners of HIV-positive pregnant women provides highly effective prevention benefits during an important 'season of risk' when men may have higher HIV acquisition risk from their partner if she is viremic (during the first few months after ART initiation, post-partum ART discontinuation or due to viral resistance), or from outside partners.

The investigators will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women who are randomized to the HIVST arm, achieves higher uptake of their male partner's testing and linkages to HIV care and prevention among male partners, compared to invitation letters for fast track testing in the clinic (the standard of care). The investigators will recruit HIV-positive women ≥18 years accessing PMTCT B+ programs in Kampala, who have a male partner of unknown HIV status. Women will be randomized to the intervention (HIVST) or the control arm (invitation letters to deliver to partners to come for fast-track testing at the Antenatal Care (ANC) clinic where she receives care.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: HIV Self-testing of Men to Increase Testing and Prevention Uptake Among Male Partners and Improve Postpartum ART Use in PMTCT B+ Programs in Uganda
Actual Study Start Date : May 17, 2018
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Active Comparator: HIV Self-test kit Behavioral: HIV self-test kit
We will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women overcomes their male partners' reluctance to be tested in PMTCT clinics. Pregnant women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.

Active Comparator: Invitation letter-standard of care Behavioral: Standard of Care
In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.




Primary Outcome Measures :
  1. Evaluation whether the secondary distribution of HIV self-tests to male partners of HIV-infected Ugandan women in PMTCT B+ is associated with effective post-partum ART continuation. [ Time Frame: Up to 12 months post-partum ]

    The outcome measure is:

    ART continuation at 12 months post-partum as measured by self-reported ART usage and adherence


  2. Evaluation whether the secondary distribution of HIV self-tests to male partners of HIV-infected Ugandan women in PMTCT B+ is associated with effective post-partum viral suppression [ Time Frame: Up to 12 months post-partum ]

    The outcome measure is:

    Viral suppression at 12 months post-partum as measured by viral load testing


  3. Evaluate whether the secondary distribution of HIV self-tests to male partners of HIV-infected Ugandan women in PMTCT B+ increases the proportion of male partners who test for HIV [ Time Frame: Up to 12 months post-partum ]
    The outcome measure is the proportion of men who test for HIV in the self-test arm to men who test for HIV in the standard of care arm

  4. Evaluate whether the secondary distribution of HIV self-tests to male partners of HIV-infected Ugandan women in PMTCT B+ is associated with male partners uptake of ART if they test HIV-positive [ Time Frame: Up to 12 months post-partum ]

    The outcome measure is:

    The proportion of HIV-positive men who initiate ART in the self-test arm to the standard of care arm


  5. Evaluate whether the secondary distribution of HIV self-tests to male partners of HIV-infected Ugandan women in PMTCT B+ is associated with male partners uptake of PrEP if they test HIV-negative [ Time Frame: Up to 12 months post-partum ]

    The outcome measure is:

    The proportion of HIV-negative men who initiate PrEP in the self-test arm to the standard of care arm


  6. To evaluate the acceptability of HIV self-testing among pregnant women taking part in PMTCT B+, their male partners, and their providers [ Time Frame: Up to 12 months post-partum ]

    The outcome measure is:

    HIV-infected pregnant women, their male partners, and their providers perspectives and views on HIV self-testing evaluated by an inductive content analytic approach conducted through qualitative interviews




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   See eligibility criteria below
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Eligibility

For all participants

  • Able and willing to provide written informed consent
  • Able and willing to provide adequate locator information for study retention purposes

For women

  • Age ≥18
  • Currently pregnant
  • HIV-positive based on positive rapid HIV tests, according to national algorithm
  • Not currently enrolled in an HIV treatment study
  • Male partner not known to be HIV-positive or has not tested in the past 3 months

For men

- In partnership with an HIV-positive pregnant woman in PMTCT B+


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03484533


Locations
Layout table for location information
Uganda
Infectious Disease Institute
Kampala, Uganda
Sponsors and Collaborators
University of Washington
National Institute of Mental Health (NIMH)
Harvard University
University of North Carolina, Chapel Hill
Investigators
Layout table for investigator information
Principal Investigator: Connie Celum, MD MPH University of Washington
  Study Documents (Full-Text)

Documents provided by Connie Celum, University of Washington:
Study Protocol  [PDF] March 6, 2018


Layout table for additonal information
Responsible Party: Connie Celum, Professor, University of Washington
ClinicalTrials.gov Identifier: NCT03484533     History of Changes
Other Study ID Numbers: STUDY00002257
R01MH113434 ( U.S. NIH Grant/Contract )
First Posted: April 2, 2018    Key Record Dates
Last Update Posted: January 17, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No